ResMed Inc. (RMD) earnings on April 30, 2026
Prior outlook: Pessimistic Outcome: Accurate
ResMed's stock dropped after reporting earnings, falling as much as 7% during the day before ending down about 4%. Investors were concerned about the company's relatively weak performance.
RMD price around the earnings
205.03
Change: -4.0%
2026-05-01, 19:59 UTC
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- Market open
- No trading (market closed)
- Starting price
Prior thesis
Prior outlook: Pessimistic Outcome: Accurate
- Thesis published
Analysts cautious — risk outweighs reward.
Analysts expect modest growth for the company, but the stock is underperforming the market and facing recent analyst downgrades. There is limited upside potential according to price targets, and risks appear to outweigh potential rewards.
Context analyzed before publication
- Summary
- Analysts cautious — risk outweighs reward.
- Reasoning
- The company has shown modest growth historically, but the stock is underperforming the market and facing recent analyst downgrades. The scenario is pessimistic according to price targets, with risks appearing to outweigh potential rewards.
- Playbook
- Given the weak technicals and analyst concerns, the current scenario does not favor new positions until the outlook improves.
- Trend
- Outlook remains negative over past five sessions.
Analysts
Drivers
-
Analysts
Negative
Despite a generally positive average price target, some analysts have recently lowered their targets, suggesting caution. This mixed analyst sentiment, combined with the limited optimistic potential from the current price to the average target, indicates a less favorable risk-reward scenario.
Evidence
- Analyst consensus
- Buy
- Consensus average (1-5)
- 2.17
- Analysts covering the stock
- 15
- Average price target
- 292.33
- Lowest price target
- 230
- Highest price target
- 345
- Upside to price target
- 32.1%
- Quarterly earnings growth
- 13.9%
- Revenue growth
- 11%
- Forward EPS
- 12.18
- Trailing EPS
- 10.11
- Analyst moves in the last 60 days
- 1
- Strong buy: 3
- Buy: 7
- Hold: 7
- Sell: 1
- Strong sell: 0
- Strong buy
- 3
- Buy
- 7
- Hold
- 7
- Sell
- 1
- Strong sell
- 0
- April 9, 2026 · Citigroup: Maintains rating (Buy → Buy)
News and sentiment
Drivers
-
News & sentiment
Neutral
There have been no significant positive news events, and while social media sentiment is positive, it is on low volume, suggesting limited impact. The lack of strong directional news or sentiment makes it difficult to anticipate a significant price move based on these factors.
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- Low
- Normalized volume
- 33%
News
Sources (1)
- Citigroup Maintains Buy on ResMed, Lowers Price Target to $340 — Benzinga
Technicals
Drivers
-
Technical
Negative
The stock's recent performance is significantly weaker than the overall market, indicating strong downward price pressure. The current price is much closer to the nearest support level than the resistance level, suggesting a higher probability of a pessimistic scenario than an optimistic one.
Evidence
- Average true range (ATR)
- 2.3%
- Distance to 52-week high
- -24.7%
- 14-day change (14d)
- -0.8%
- 30-day change
- -10.5%
- 30-day relative strength
- -14.3%
- Benchmark change
- +3.8%
- Nearest support
- 218.39
- Nearest resistance
- 252.53
- Volume accumulation ratio
- 0.99
Trends
Evidence
- Average earnings surprise
- +0.8%
- January 29, 2026: actual EPS 2.81 vs estimate 2.72 (surprise +3.1%)
- October 30, 2025: actual EPS 2.37 vs estimate 2.44 (surprise -3.0%)
- July 31, 2025: actual EPS 2.55 vs estimate 2.48 (surprise +2.8%)
- April 23, 2025: actual EPS 2.37 vs estimate 2.36 (surprise +0.4%)
Expected move
There is no implied-move data available for this event.
Reactions over its last 19 earnings
- Median move
- 4.1%
- 75th percentile move
- 7.6%
- 90th percentile move
- 11.7%
- Up / down moves
- 9 / 10
- Average up move
- +6.8%
- Average down move
- -5.4%
Monitoring and close
What ResMed Inc. reported
There is no monitoring data available for this event.
Pre-market second reading after the results
There is no second reading available for this event.
How the stock reacted
- Outcome
- Accurate
- Consolidated
- -4.0%
- Max favorable move (MFE)
- 7%
- Max adverse move (MAE)
- 0%